Jazz Pharmaceuticals (JAZZ) EBITDA Margin (2010 - 2026)
Jazz Pharmaceuticals (JAZZ) recorded quarterly EBITDA Margin of 31.49% in Q1 2026, up 48.2% quarter-over-quarter from 21.25% in Q4 2025, and up 2375.0% on a YoY basis from 1.27% in Q1 2025.
Jazz Pharmaceuticals (JAZZ) EBITDA Margin (2010 - 2026) Analysis & Trends
Jazz Pharmaceuticals' EBITDA Margin history runs 17 years deep, the most recent figure standing at 31.49% for Q1 2026.
- In Q1 2026, EBITDA Margin rose 2375.0% year-over-year to 31.49%; the TTM figure through Mar 2026 stood at 0.85% (down 1856.0% YoY), while the FY2025 annual figure was 10.08%, down 2769.0% from the prior year.
- EBITDA Margin was 31.49% for Q1 2026 at Jazz Pharmaceuticals, up from 21.25% in the prior quarter.
- In the past five years, EBITDA Margin ranged from a high of 31.49% in Q1 2026 to a low of 65.64% in Q2 2025.
- Historically, EBITDA Margin has averaged 6.55% across 5 years, with a median of 12.11% in 2023.
- The sharpest annual moves came in 2023 and 2025: EBITDA Margin jumped 3920 bps in 2023, then sank 8512 bps in 2025.
- A 5-year view of EBITDA Margin shows it stood at 27.09% in 2022, then surged by 145 bps to 12.11% in 2023, then surged by 45 bps to 17.53% in 2024, then increased by 21 bps to 21.25% in 2025, then surged by 48 bps to 31.49% in 2026.
- The last three EBITDA Margin figures came in at 31.49% (Q1 2026), 21.25% (Q4 2025), and 5.11% (Q3 2025), per Business Quant data.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | EBITDA Margin (Qtr) |
|---|---|---|---|---|---|
| 1 | Alterity Therapeutics | 925,601.88 Bn | 925,601.85 Bn | - | - |
| 2 | Belite Bio | 58,560.00 Bn | 58,560.00 Bn | - | - |
| 3 | Quantum Biopharma | 17,284.41 Bn | 17,284.40 Bn | - | - |
| 4 | Legend Biotech | 2,809.00 Bn | 2,808.71 Bn | 242.10 Mn | -6.43% |
| 5 | Evaxion A | 1,334.43 Bn | 1,334.42 Bn | - | - |
| 6 | Akari Therapeutics | 1,312.27 Bn | 1,312.26 Bn | - | - |
| 7 | Psyence Biomedical | 212.16 Bn | 212.16 Bn | - | - |
| 8 | Vertex Pharmaceuticals | 114.83 Bn | 107.58 Bn | 2.59 Bn | 38.10% |
| 9 | Abivax | 91.96 Bn | 91.96 Bn | - | - |
| 10 | Jazz Pharmaceuticals | 13.91 Bn | 12.06 Bn | 934.80 Mn | 31.49% |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 31.49% |
| Dec 31, 2025 | 21.25% |
| Sep 30, 2025 | 5.11% |
| Jun 30, 2025 | -65.64% |
| Mar 31, 2025 | 7.74% |
| Dec 31, 2024 | 17.53% |
| Sep 30, 2024 | 24.67% |
| Jun 30, 2024 | 19.48% |
| Mar 31, 2024 | -6.08% |
| Dec 31, 2023 | 12.11% |
| Sep 30, 2023 | 17.73% |
| Jun 30, 2023 | 16.47% |
| Mar 31, 2023 | 14.12% |
| Dec 31, 2022 | -27.09% |
| Sep 30, 2022 | 2.63% |
| Jun 30, 2022 | 9.17% |
| Mar 31, 2022 | 10.76% |
| Dec 31, 2021 | 5.51% |
| Sep 30, 2021 | 3.38% |
| Jun 30, 2021 | -9.26% |